Physician profile
Anna Walls
NPI 1104013036
$875.85
in general payments reported to CMS, 2019-2025
16 companies · $131 in 2025
The $131 reported for 2025 was more than what a typical Pediatrics (Nurse Practitioner) provider received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.84 · 2022: $103 · 2023: $214 · 2024: $336 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $210.87 | 2022-2025 | Bexsero, Pediarix, Rotarix |
| Sanofi Pasteur INC. | $90.65 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $84.51 | 2021-2025 | Vaxneuvance, Gardasil, Gardasil 9 |
| Atricure, INC. | $81.93 | 2023 | |
| Pfizer INC. | $79.32 | 2021-2023 | |
| Ironshore Pharmaceuticals INC. | $75.71 | 2022-2024 | Jornay Pm |
| Corium, LLC | $53.94 | 2023 | Azstarys |
| Sunovion Pharmaceuticals INC. | $33.98 | 2021 | |
| Supernus Pharmaceuticals, INC. | $25.37 | 2022-2023 | Qelbree |
| Photonicare INC | $25.32 | 2024 | Otosight Middle Ear Scope |
| Astrazeneca Pharmaceuticals LP | $24.33 | 2024 | Flumist Quadrivalent |
| Tris Pharma INC | $21.75 | 2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $21.59 | 2022 | |
| Collegium Pharmaceutical, INC. | $18.09 | 2025 | Jornay Pm |
| Cipher Pharmaceuticals US LLC | $15.90 | 2025 | Natroba, Spinosad |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Walls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.